Archive · 13 Jan 2026
UK Approves Controversial Puberty Blocker Trial Amid Backlash
The UK is starting a big study in January to test drugs that stop puberty in children who feel they might be transgender.
Over 200 kids, as young as eight, will take part.
These drugs were banned last year because experts weren't sure if they were safe.
The new study will look at how the drugs affect kids' bodies and minds.
Some people, like doctors and politicians, are very upset and say the study could hurt kids.
They want the study to stop.
Others, like the researchers, say it's important to find out if the drugs help or harm kids.
The study has a lot of money and will last about four years.
Many people are watching closely to make sure everything is done safely.
The UK is launching a clinical trial in January to study the effects of puberty blockers on children with gender dysphoria.
Over 200 children aged 8-16 will participate, with the trial focusing on physical, social, emotional health, and brain development.
The trial follows a ban on puberty blockers due to concerns about their safety and lack of long-term data.
The trial has sparked massive backlash, with threats of legal action and petitions from activists, politicians, and public figures.
Critics argue the trial is unethical and could harm children, while supporters believe it is necessary to understand the benefits and risks.
- Who
- Over 200 children aged 8-16 who identify as transgender, researchers from King’s College London, and various political figures and activists.
- What
- A new clinical trial involving puberty blockers for children with gender dysphoria.
- When
- The trial is set to begin in January, with preliminary results expected in about four years.
- Where
- United Kingdom, conducted by NHS Children and Young People’s Gender Services.
- Why
- To assess the effects of puberty blockers on physical, social, and emotional health, and brain development, amid concerns about their safety and efficacy.
- Trial Name
- Pathway
- Participants
- Over 200 children aged 8-16
- Trial Duration
- 4 years
- Budget
- £11 million
- Lead Institution
- King’s College London
- Ethical Approval
- Granted by Health Research Authority
- Key Concerns
- Potential harm to cognitive function, bone health, fertility, and long-term health
- Opposition
- Legal threats, petitions, and political backlash